2. A) #PROfound looks at #OS analysis of patients #prostatecancer w/ #olaparib vs #abi/#enza. Better responses in pts w/ BRCA1/2, less clear benefit for pts w/ CDK12/ATM mutations
Current #SOC: @NCCN 2nd line: Docetaxel?- need some #expert help!
"Fall in US cancer death rates: Time to pop the champagne?": the amazing @oncology_bg and myself comment on the big debate about who deserves credit for the progress in our @EClinicalMed commentary: thelancet.com/journals/eclin…. Read along for a brief tweetorial!
Researchers found that since 1991 the cancer death rate has dropped 29%, but the 2.2% decline in mortality rates from 2016 to 2017 was the largest single-year decline in cancer mortality ever reported.
Since this fall was primarily driven by lung cancer, many experts speculated that this was the success story of treatment advances which has dramatically changed over the decade with the introduction of genomic and immunotherapy-based drugs.